Physician profile
Lowell R Schmeltz
NPI 1538112917
$1,301,479.69
in general payments reported to CMS, 2019-2025
62 companies · $227K in 2025
The $227K reported for 2025 was more than what 99% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269K · 2020: $154K · 2021: $200K · 2022: $159K · 2023: $136K · 2024: $156K · 2025: $227K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $368K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $47K · Travel and Lodging: $45K · Consulting Fee: $43K · Food and Beverage: $16K · Long Term Medical Supply Or Device Loan: $49.95 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $368,230.72 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $46,569.00 |
| Travel and Lodging | $45,443.00 |
| Consulting Fee | $42,714.50 |
| Food and Beverage | $15,949.93 |
| Long Term Medical Supply Or Device Loan | $49.95 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $643,192.04 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $249,313.42 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $109,570.87 | 2019-2025 | |
| Abbott Laboratories | $72,893.43 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Freestyle Insulinx |
| Dexcom, INC. | $59,633.00 | 2019-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor, Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $56,580.08 | 2019-2025 | Jardiance |
| Genzyme Corporation | $38,393.74 | 2025 | |
| Tandem Diabetes Care, INC. | $17,847.05 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Bayer Healthcare Pharmaceuticals INC. | $17,413.94 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $9,979.53 | 2019-2023 | Verquvo, Januvia, Steglujan |
| Xeris Pharmaceuticals, INC. | $8,691.50 | 2020-2025 | Recorlev, Gvoke Hypopen |
| Abbvie INC. | $5,276.98 | 2019-2025 | Synthroid |
| Insulet Corporation | $3,877.22 | 2019-2025 | Omnipod |
| Vistapharm, INC. | $2,750.00 | 2021 | |
| Amgen INC. | $1,360.75 | 2019-2025 | Tepezza, Evenity, Prolia |
Show all 59 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lowell Schmeltz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.